Tin tức & Cập nhật
Xem bài viết Ung thư
Xem

CtDNA testing predicts recurrence, enables personalized management in MIBC
Circulating tumour DNA (ctDNA) testing after neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) may inform patients with muscle-invasive bladder cancer (MIBC) of their risk for recurrence and allows personalized postoperative management in MIBC, results of the TOMBOLA trial have shown.
CtDNA testing predicts recurrence, enables personalized management in MIBC
12 giờ trước
Excessive IPFD ups risk of pancreatic diseases
Excessive intrahepatic fat deposition (IPFD) appears to contribute to an increased risk of major pancreatic disease, suggests a recent study, noting the potential benefits of IPFD reduction in preventing pancreatitis and pancreatic cancer.
Excessive IPFD ups risk of pancreatic diseases
một ngày trước
Enzalutamide plus leuprolide delays metastasis, progression in prostate cancer
Prostate cancer patients treated with enzalutamide plus leuprolide have a higher probability of remaining free of distant metastasis, castration resistance, symptomatic progression, and first symptomatic skeletal event (SSE) at 5 years than those treated with leuprolide alone, as shown by the results of the EMBARK study.
Enzalutamide plus leuprolide delays metastasis, progression in prostate cancer
06 May 2026
Ipilimumab plus nivolumab prolongs survival in melanoma with brain metastases
Treatment with ipilimumab plus nivolumab improves long-term survival in melanoma patients with asymptomatic brain metastases, according to the results of the NIBIT-M2 trial presented at AACR 2026.





